Sunesis starts dosing in Phase Ib/II trial of SNS-062 for B-cell malignancies

Sunesis Pharmaceuticals has started dosing patients in a Phase Ib/II clinical trial of SNS-062 to treat patients with B-cell malignancies such as chronic lymphocytic leukaemia (CLL), small lymphocytic leukaemia, Waldenstrom ’s macroglobulinemia and ma…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news